JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a price target of $32.
August 12, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Kura Oncology and maintained a price target of $32.
The reiteration of a Market Outperform rating and a maintained price target of $32 by JMP Securities is a positive signal for Kura Oncology. This could boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100